Literature DB >> 21628141

Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.

Michael D Bastian1, Nicholas E Wolters, David R Bright.   

Abstract

Insulin therapy is crucial to the treatment of many patients with diabetes mellitus. Therefore, it is important for pharmacists to consider the clinical and economic implications of the decision between insulin pens and insulin vials and syringes. Clinically, insulin pens show an advantage through improved adherence and reduced hypoglycemic events. Furthermore, overall health care costs were either unchanged or improved in insulin pen users as compared with those using insulin vials and syringes, although little economic advantage was observed when switching from insulin vials to insulin pens. Patients tend to prefer insulin pen use based on patient satisfaction and ease of use. Through an understanding of the advantages and disadvantages of insulin pens and vials and syringes, pharmacists can help to advocate for the most appropriate insulin-delivery method to maximize clinical outcomes and to reduce overall health care spending.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628141     DOI: 10.4140/TCP.n.2011.426

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  3 in total

1.  Analysis of patient satisfaction with a prefilled insulin injection device in patients with type 1 and type 2 diabetes.

Authors:  Thorsten Siegmund
Journal:  J Diabetes Sci Technol       Date:  2011-09-01

2.  Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills.

Authors:  Andreas Pfützner; Christina Schipper; Marcus Niemeyer; Marianne Qvist; Andrea Löffler; Thomas Forst; Petra B Musholt
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

3.  Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.

Authors:  Leona Plum-Mörschel; Oliver Klein; Gursharan Singh; Sundara Moorthi Nainar Murugesan; Ashwani Marwah; Nirant Sharma; Jayanti Panda; Subramanian Loganathan; Gopu Chandrasekharan Lakshmi; Sandeep N Athalye
Journal:  Diabetes Obes Metab       Date:  2022-06-06       Impact factor: 6.408

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.